Anti-CD20 disease modifying therapies are associated with severe COVID-19 disease course in multiple sclerosis


  • In patients with multiple sclerosis (MS), severe course of coronavirus disease (COVID-19) was associated with certain demographic/clinical risk factors, such as being older or male, and ocrelizumab and rituximab medication.

Why this matters

  • COVID-19 has a major impact on health, including in people with MS.

  • Examining the risk factors of COVID-19 severity, epidemiological factors and use of disease modifying therapies (DMTs), is required to further understand its influence on MS.